GSK Annual Report Details Turnover Performance
GSK plc has released its 2024 Annual Report, providing detailed insights into the company's turnover across various therapeutic areas and geographic regions. The report offers a review of financial performance over recent years.
Pharmaceutical company GSK plc has published its 2024 Annual Report, offering a comprehensive overview of the company's financial performance. The report includes detailed information on the company's turnover breakdown by therapeutic area and geographic market over a three-year period.
According to the report, GSK's total turnover reached £31.376 billion in 2024, an increase from £30.328 billion in the previous year. The US market accounted for £16.384 billion of turnover in 2024, Europe for £6.666 billion, and international markets for £8.326 billion.
Vaccine turnover experienced a slight decrease, amounting to £9.138 billion in 2024 compared to £9.864 billion in 2023. This decline was influenced by a significant drop in RSV and influenza vaccine sales, although shingles and meningitis vaccine sales showed resilience or growth in certain markets.
Specialty Medicines turnover saw an increase, reaching £11.810 billion, with notable growth in the oncology segment. Sales of HIV medications continued their strong upward trajectory, contributing significantly to this segment's performance.